The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Open accessAbstract
BACKGROUND: Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative neoplasms with nonmutated JAK2 is obscure, and the diagnosis of these neoplasms remains a challenge. METHODS: We performed exome sequencing of samples obtained from 151 patients with myeloproliferative neoplasms. The mutation status of the gene encoding calreticulin (CALR) was assessed in an additional 1345 hematologic cancers, 1517 other cancers, and 550 controls. We established phylogenetic trees using hematopoietic colonies. We assessed calreticulin subcellular localization using immunofluorescence and flow cytometry. RESULTS: Exome sequencing identified 1498 mutations in 151 patients, with medians of 6.5, 6.5, and 13.0 mutations per patient in samples of polycythemia vera, essential thrombocythemia, and myelofibrosis, respectively. Somatic CALR mutations were found in 70 to 84% of samples of myeloproliferative neoplasms with nonmutated JAK2, in 8% of myelodysplasia samples, in occasional samples of other myeloid cancers, and in none of the other cancers. A total of 148 CALR mutations were identified with 19 distinct variants. Mutations were located in exon 9 and generated a +1 base-pair frameshift, which would result in a mutant protein with a novel C-terminal. Mutant calreticulin was observed in the endoplasmic reticulum without increased cell-surface or Golgi accumulation. Patients with myeloproliferative neoplasms carrying CALR mutations presented with higher platelet counts and lower hemoglobin levels than patients with mutated JAK2. Mutation of CALR was detected in hematopoietic stem and progenitor cells. Clonal analyses showed CALR mutations in the earliest phylogenetic node, a finding consistent with its role as an initiating mutation in some patients. CONCLUSIONS: Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a majority of patients with myeloproliferative neoplasms with nonmutated JAK2. (Funded by the Kay Kendall Leukaemia Fund and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“But many of the most commonly seen mutations in CHIP are also recurrent drivers of AML 64, myelodysplastic syndrome (MDS) 65–67, myeloproliferative neoplasms 68, and certain lymphomas 69,70.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [68]
In the citing paper
“Calreticulin gene (CALR) mutations frequently occur in Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV) [188–190].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Self-citationA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,062
Self-citationLevine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationClinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Chao MP, 2010, Sci Transl Med, 2, 63ra94
Cited by
Sorted by citations
Items 401–500 of 1,002
Shivarov, V. S., Ivanova, M., & Tiu, R. V. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.7 · Cited by 38
Bartels, S., Lehmann, U., Büsche, G., Schlué, J., Mozer, M., Stadler, J., Triviai, I., Alchalby, H., Kröger, N. M., & Kreipe, H. H. (2014) · Leukemia · doi:10.1038/leu.2014.277 · Cited by 38
Myeloproliferative Neoplasms: JAK2 Signaling Pathway as a Central Target for Therapy
Pasquier, F., Cabagnols, X., Secardin, L., Plo, I., & Vainchenker, W. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.06.014 · Cited by 45
Epidemiology of MPN: What Do We Know?
Anderson, L. A., & McMullin, M. F. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0228-z · Cited by 38
Fontanelli, G., Baratè, C., Ciabatti, E., Guerrini, F., Grassi, S., Re, M. D., Morganti, R., Petrini, I., Arici, R., Barsotti, S., et al. (2015) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12404 · Cited by 39
Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms
Ha, J., & Kim, Y. (2014) · Annals of Laboratory Medicine · doi:10.3343/alm.2015.35.1.22 · Cited by 38
Integrating mutation variant allele frequency into clinical practice in myeloid malignancies
Sallman, D. A., & Padron, E. (2016) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2016.04.003 · Cited by 39
Hansen, I. O., Sørensen, A. L., & Hasselbalch, H. C. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12787 · Cited by 38
Mejía-Ochoa, M., Toro, P. A. A., & Cardona‐Arias, J. A. (2019) · BMC Cancer · doi:10.1186/s12885-019-5764-4 · Cited by 38
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib
Patel, A. A., & Odenike, O. M. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00596-z · Cited by 39
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives
Loscocco, G. G., & Vannucchi, A. M. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03335-7 · Cited by 38
Self-citationPersistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation
Girardot, M., Pecquet, C., Chachoua, I., Hees, J. V., Guibert, S., Ferrant, A., Knoops, L., Baxter, E. J., Beer, P. A., Giraudier, S., et al. (2014) · Oncogene · doi:10.1038/onc.2014.60 · Cited by 38
Self-citationLau, W. W. Y., Hannah, R., Green, A. R., & Göttgens, B. (2015) · Blood · doi:10.1182/blood-2014-12-618074 · Cited by 38
Self-citationLaboratory Investigation of Myeloproliferative Neoplasms (MPNs)
Busque, L., Porwit‐MacDonald, A., Day, R., Olney, H. J., Leber, B. F., Éthier, V., Sirhan, S., Foltz, L., Prchal, J. F., Kamel‐Reid, S., et al. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw131 · Cited by 43
Rozovski, U., Verstovšek, S., Manshouri, T., Dembitz, V., Božinović, K., Newberry, K. J., Zhang, Y., Bove, J. E., Pierce, S. A., Kantarjian, H. M., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.149765 · Cited by 37
Varricchio, L., Falchi, M., Dall’Ora, M., Benedittis, C. D., Ruggeri, A., Uversky, V. N., & Migliaccio, A. R. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00096 · Cited by 37
How I treat the blast phase of Philadelphia chromosome–negative myeloproliferative neoplasms
Odenike, O. M. (2018) · Blood · doi:10.1182/blood-2018-03-785907 · Cited by 37
Cytokines frequently implicated in myeloproliferative neoplasms
Wang, Y., & Zuo, X. (2019) · Cytokine X · doi:10.1016/j.cytox.2019.100005 · Cited by 39
The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells
Craver, B. M., Nguyen, T. K., Nguyen, J. M., Nguyen, H., Huynh, C., Morse, S. J., & Fleischman, A. G. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0157-6 · Cited by 37
ZBTB33 Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing
Beauchamp, E. M., Leventhal, M. J., Bernard, E., Hoppe, E. R., Todisco, G., Creignou, M., Gallì, A., Castellano, C. A., McConkey, M. E., Tarun, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0224 · Cited by 37
Self-citationEssential thrombocythemia: challenges in clinical practice and future prospects
Godfrey, A. L., Green, A. C., & Harrison, C. N. (2022) · Blood · doi:10.1182/blood.2022017625 · Cited by 37
Self-citationIndividualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia
Eiring, A. M., & Deininger, M. W. (2014) · Genome biology · doi:10.1186/s13059-014-0461-8 · Cited by 38
Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms
Ueda, K., Ikeda, K., Ikezoe, T., Harada‐Shirado, K., Ogawa, K., Hashimoto, Y., Sano, T., Ohkawara, H., Kimura, S., Shichishima-Nakamura, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017004457 · Cited by 37
The Microenvironment in Myeloproliferative Neoplasms
Ramanathan, G., & Fleischman, A. G. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.11.003 · Cited by 39
Calreticulin as a marker and therapeutic target for cancer
Zhang, M., Xiao, J., Liu, J., Bai, X., Zeng, X., Zhang, Z., & Liu, F. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00937-7 · Cited by 37
Grockowiak, É., Korn, C., Rak, J. M., Lysenko, V., Hallou, A., Panvini, F. M., Williams, M., Fielding, C., Fang, Z., Khatib-Massalha, E., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00607-x · Cited by 36
Self-citationTherapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer, H. L., & Mesa, R. A. (2014) · Hematology · doi:10.1182/asheducation-2014.1.277 · Cited by 36
Mutant calreticulin‐expressing cells induce monocyte hyperreactivity through a paracrine mechanism
Garbati, M. R., Welgan, C. A., Landefeld, S. H., Newell, L. F., Agarwal, A., Dunlap, J. B., Chourasia, T. K., Lee, H.-J., Elferich, J., Traer, E. A., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24245 · Cited by 36
The Role of PTEN in Myeloid Malignancies
Morotti, A., Panuzzo, C., Crivellaro, S., Carrà, G., Torti, D., Guerrasio, A., & Saglio, G. N. (2015) · Hematology Reports · doi:10.4081/hr.2015.6027 · Cited by 38
Shen, W., Szankasi, P., Sederberg, M. C., Schumacher, J. A., Frizzell, K., Gee, E. P. S., Patel, J. L., South, S. T., Xu, X., & Kelley, T. W. (2016) · British Journal of Haematology · doi:10.1111/bjh.13921 · Cited by 36
Nasillo, V., Riva, G., Paolini, A., Forghieri, F., Roncati, L., Lusenti, B., Maccaferri, M., Messerotti, A., Pioli, V., Gilioli, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041906 · Cited by 36
A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms
Guijarro-Hernández, A., & Vizmanos, J. L. (2021) · Cancers · doi:10.3390/cancers13050984 · Cited by 37
Cattaneo, D., Croci, G. A., Bucelli, C., Tabano, S. M., Cannone, M. G., Gaudioso, G., Barbanti, M. C., Barbullushi, K., Bianchi, P. I., Fermo, E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637116 · Cited by 36
A Comprehensive Review of Pacritinib in Myelofibrosis
Verstovšek, S., & Komrokji, R. S. (2015) · Future Oncology · doi:10.2217/fon.15.200 · Cited by 36
Bonzheim, I., Mankel, B., Klapthor, P., Schmidt, J., Hinrichsen, T., Wachter, O., Fend, F., & Quintanilla‐Martínez, L. (2015) · Blood · doi:10.1182/blood-2014-12-616847 · Cited by 36
CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner
Abdelouahab, H., Zhang, Y., Wittner, M., Oishi, S., Fujii, N., Besancenot, R., Plo, I., Ribrag, V., Solary, É., Vainchenker, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10789 · Cited by 36
JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms
O’Sullivan, J., & Harrison, C. N. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.050 · Cited by 37
Self-citationMARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling
Kollmann, K., Nangalia, J., Warsch, W., Quentmeier, H., Bench, A. J., Boyd, E., Scott, M. A., Drexler, H. G., & Green, A. R. (2014) · Leukemia · doi:10.1038/leu.2014.285 · Cited by 37
Self-citationIsolation of T cell receptors targeting recurrent neoantigens in hematological malignancies
Tubb, V., Schrikkema, D. S., Croft, N. P., Purcell, A. W., Linnemann, C., Freriks, M. R., Chen, F. E., Long, H. M., Lee, S. P., & Bendle, G. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0386-y · Cited by 36
Fel, A., Bogucka, A. E., Petrides, P. E., & Wiśniewski, J. R. (2019) · Proteomes · doi:10.3390/proteomes7020020 · Cited by 35
CALR mutation studies in chronic neutrophilic leukemia
Lasho, T. L., Elliott, M. A., Pardanani, A. D., & Tefferi, A. (2014) · American Journal of Hematology · doi:10.1002/ajh.23665 · Cited by 34
Quantification of the Mutant CALR Allelic Burden by Digital PCR
Mansier, O., Migeon, M., Saint-Lezer, A., James, C., Verger, E., Robin, M., Socié, G., Bidet, A., Mahon, F., Cassinat, B., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.07.007 · Cited by 34
Helman, R., Pereira, W. O., Marti, L. C., Campregher, P. V., Puga, R. D., Hamerschlak, N., CHIATTONE, C. S., & Santos, F. P. D. S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14327 · Cited by 34
Managing side effects of JAK inhibitors for myelofibrosis in clinical practice
Saeed, I., McLornan, D. P., & Harrison, C. N. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1337507 · Cited by 34
Self-citationSalati, S., Prudente, Z., Genovese, E., Pennucci, V., Rontauroli, S., Bartalucci, N., Mannarelli, C., Ruberti, S., Zini, R., Rossi, C., et al. (2017) · Stem Cells and Development · doi:10.1089/scd.2017.0137 · Cited by 34
Self-citationCuthbert, D., & Stein, B. L. (2019) · Journal of Blood Medicine · doi:10.2147/jbm.s189922 · Cited by 36
Aetiology of Myeloproliferative Neoplasms
McMullin, M. F., & Anderson, L. A. (2020) · Cancers · doi:10.3390/cancers12071810 · Cited by 37
Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
Shallis, R. M., Zeidan, A. M., Wang, R., & Podoltsev, N. A. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.11.005 · Cited by 34
Celik, H., Krug, E., Zhang, C. R., Han, W., Issa, N., Koh, W. K., Bjeije, H., Kukhar, O., Allen, M., Li, T., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1652 · Cited by 40
Randi, M. L., Geranio, G., Bertozzi, I., Micalizzi, C., Ramenghi, U., Tucci, F., Notarangelo, L. D., Ladogana, S., Menna, G., Giordano, P., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13329 · Cited by 34
Janus kinase inhibitors for the treatment of myeloproliferative neoplasms
Rosenthal, A. C., & Mesa, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.913024 · Cited by 34
Lim, K.-H., Chang, Y.-C., Chen, C.-J., Lin, H.-C., Wang, W.-T., Chiang, Y.-L., Cheng, H.-I., Su, N.-W., Lin, J., Chang, Y.-F., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.21 · Cited by 33
Assessment ofCALRmutations in myelofibrosis patients, post-allogeneic stem cell transplantation
Haslam, K., Langabeer, S. E., Molloy, K., McMullin, M. F., & Conneally, E. (2014) · British Journal of Haematology · doi:10.1111/bjh.12904 · Cited by 33
miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia
Navarro, A., Pairet, S., Álvarez‐Larrán, A., Pons, A., Ferrer, G., Longarón, R., Fernández‐Rodríguez, C., Camacho, L., Monzó, M., Besses, C., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.10 · Cited by 33
Bjørn, M. E., & Hasselbalch, H. C. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1284583 · Cited by 33
Fenerich, B. A., Fernandes, J. C., Alves, A. P. N. R., Coelho‐Silva, J. L., Scopim‐Ribeiro, R., Scheucher, P. S., Eide, C. A., Tognon, C. E., Druker, B. J., Rego, E. M., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0102-5 · Cited by 34
Recurrent deletions in clonal hematopoiesis are driven by microhomology-mediated end joining
Feldman, T., Bercovich, A., Moskovitz, Y., Chapal-Ilani, N., Mitchell, A., Medeiros, J. J. F., Biezuner, T., Kaushansky, N., Minden, M. D., Gupta, V. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22803-y · Cited by 34
Boissinot, M., Vilaine, M., & Hermouet, S. (2014) · Cancers · doi:10.3390/cancers6031631 · Cited by 34
Tong, D., Yu, M., Guo, L., Li, T., Li, J., Novakovic, V. A., Dong, Z., Tian, Y., Kou, J., Bi, Y., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3228-6 · Cited by 33
Self-citationTodor, S. B., Ichim, C., Boicean, A., & Mihăilă, R. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46080496 · Cited by 32
Xu, N., Ding, L., Yin, C., Zhou, X., Li, L., Li, Y., Lu, Q., & Liu, X. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2248-0 · Cited by 32
Are we altering the natural history of primary myelofibrosis?
Savona, M. R. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.04.012 · Cited by 32
Mesa, R. A., Scherber, R. M., & Geyer, H. L. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.983098 · Cited by 34
Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms
Duncombe, A. S., Anderson, L. A., James, G., de Vocht, F., Fritschi, L., Mesa, R. A., Clarke, M. J., & McMullin, M. F. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000327 · Cited by 32
Transfusion Indications for Patients with Cancer
Watkins, T. C., Surowiecka, M., & McCullough, J. (2015) · Cancer Control · doi:10.1177/107327481502200106 · Cited by 32
Shepherd, M. S., Li, J., Wilson, N. K., Oedekoven, C. A., Li, J., Belmonte, M., Fink, J., Prick, J. C. M., Pask, D. C., Hamilton, T. L., et al. (2018) · Blood · doi:10.1182/blood-2017-12-821066 · Cited by 33
Self-citationUse of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study
Kristensen, D. T., Øvlisen, A. K., Jakobsen, L. H., Severinsen, M. T., Hannig, L. H., Starklint, J., Hilsøe, M. H., Vallentin, A. P., Brabrand, M., Hasselbalch, H. C., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009784 · Cited by 31
Angiogenesis in myeloproliferative neoplasms, new markers and future directions
Medinger, M., & Passweg, J. R. (2014) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-014-0142-z · Cited by 32
Hilpert, M., Legrand, C., Bluteau, D., Balayn, N., Betems, A., Bluteau, O., Villeval, J., Louache, F., Gonin, P., Debili, N., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.10.005 · Cited by 31
Insights into clonal hematopoiesis and its relation to cancer risk
Mitchell, S. R., Gopakumar, J., & Jaiswal, S. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.12.004 · Cited by 31
Álvarez‐Larrán, A., Sant’Antonio, E., Harrison, C. N., Kiladjian, J., Grießhammer, M., Mesa, R. A., Ianotto, J., Palandri, F., Hernández‐Boluda, J. C., Birgegård, G., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00204-0 · Cited by 31
Self-citationDutta, A., Nath, D., Yang, Y., Le, B. T., Rahman, M. F.-U., Faughnan, P., Wang, Z., Stuver, M., He, R., Tan, W., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01464-2 · Cited by 33
Calreticulin mutations affect its chaperone function and perturb the glycoproteome
Schürch, P. M., Malinovska, L., Hleihil, M., Losa, M., Hofstetter, M., Wildschut, M. H. E., Lysenko, V., Lakkaraju, A. K., Maat, C. A., Benke, D., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111689 · Cited by 31
Mutations, inflammation and phenotype of myeloproliferative neoplasms
Hermouet, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1196817 · Cited by 31
Analysis of platelet function and dysfunction
Jurk, K. (2014) · Hämostaseologie · doi:10.5482/hamo-14-09-0047 · Cited by 31
Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome
Asp, J., Andréasson, B., Hansson, U. P., Wasslavik, C., Abelsson, J., Johansson, P. L., & Palmqvist, L. (2016) · Haematologica · doi:10.3324/haematol.2015.138958 · Cited by 31
Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms
Bose, P., & Verstovšek, S. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1250882 · Cited by 31
Treatment of Myelofibrosis: Old and New Strategies
Iurlo, A., & Cattaneo, D. (2017) · Clinical Medicine Insights Blood Disorders · doi:10.1177/1179545x17695233 · Cited by 33
Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia
Álvarez‐Larrán, A., Senín, A., Fernández‐Rodríguez, C., Pereira, A., Arellano‐Rodrigo, E., Gómez, M., Ferrer‐Marín, F., Martínez‐López, J., Camacho, L., Colomer, D., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14762 · Cited by 31
Palandri, F., Palumbo, G. A., Iurlo, A., Polverelli, N., Benevolo, G., Breccia, M., Abruzzese, E., Tiribelli, M., Bonifacio, M., Tieghi, A., et al. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.05.013 · Cited by 31
Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis
Merlinsky, T. R., Levine, R. L., & Pronier, E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3777 · Cited by 31
Alwahsh, M., Farhat, J., Talhouni, S., Hamadneh, L., & Hergenröder, R. (2022) · EXCLI journal · doi:10.17179/excli2022-5653 · Cited by 32
Mutational profile of childhood myeloproliferative neoplasms
Karow, A., Nienhold, R., Lundberg, P., Peroni, E., Putti, M. C., Randi, M. L., & Skoda, R. C. (2015) · Leukemia · doi:10.1038/leu.2015.205 · Cited by 30
Guidelines for the management of myeloproliferative neoplasms
Choi, C. W., Bang, S., Jang, S., Jung, C. W., Kim, H., Kim, H. Y., Kim, S., Kim, Y., Park, J., & Won, J.-H. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.6.771 · Cited by 32
Pozdnyakova, O., Wu, K., Patki, A. H., Rodig, S. J., Thiele, J., & Hasserjian, R. P. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.69 · Cited by 31
Sollazzo, D., Forte, D., Polverelli, N., Perricone, M., Romano, M., Luatti, S., Vianelli, N., Cavo, M., Palandri, F., & Catani, L. (2016) · Mediators of Inflammation · doi:10.1155/2016/5860657 · Cited by 30
Piccin, A., Steurer, M., Feistritzer, C., Murphy, C., Eakins, E., Schilfgaarde, M. V., Corvetta, D., Pierro, A. M. D., Pusceddu, I., Marcheselli, L., et al. (2017) · Translational research · doi:10.1016/j.trsl.2017.02.001 · Cited by 30
Limia, C. E. G., Devalle, S., Reis, M. M., Sochacki, J., Carneiro, M., da Costa, R. M., D'Andrea, M., Padilha, T. F., Zalcberg, I. R., Solza, C., et al. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.08.006 · Cited by 30
Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
Ross, D. M., Babon, J. J., Tvorogov, D., & Thomas, D. (2021) · Haematologica · doi:10.3324/haematol.2020.262691 · Cited by 30
Melikyan, A. L., Kovrigina, A. M., Subortseva, I. N., Shuvaev, V. A., Morozova, E. V., Галактионовна, Л. Е., Afanasyev, B. V., Ageeva, T. A., Байков, В. В., Vinogradova, O., et al. (2021) · Clinical oncohematology · doi:10.21320/2500-2139-2021-14-2-262-298 · Cited by 30
Shi, Z., Liu, J., Zhao, Y., Yang, L., Cai, Y., Zhang, P., Xu, Z., Qin, T., Qu, S., Pan, L., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280320 · Cited by 31
Next-Generation Sequencing-Based Panel Testing for Myeloid Neoplasms
Kuo, F. C., & Dong, F. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0256-3 · Cited by 30
Malherbe, J. A. J., Fuller, K. A., Arshad, A., Nangalia, J., Romeo, G., Hall, S. L., Meehan, K. L., Guo, B. B., Howman, R., & Erber, W. N. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203177 · Cited by 30
Self-citationClonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation
Hirsch, P., Mamez, A., Belhocine, R., Lapusan, S., Tang, R., Suner, L., Bories, D., Marzac, C., Fava, F., Legrand, O., et al. (2016) · Leukemia · doi:10.1038/leu.2016.31 · Cited by 30
Gerds, A. T., Su, D. W., Martynova, A., Pannell, B. K., Mukherjee, S., O’Neill, C., Sekeres, M. A., & O'Connell, C. L. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.025 · Cited by 30
Chorzalska, A. D., Morgan, J. W., Ahsan, N., Treaba, D. O., Olszewski, A. J., Petersen, M., Kingston, N. M., Cheng, Y., Lombardo, K. A., Schorl, C., et al. (2018) · Blood · doi:10.1182/blood-2018-05-848408 · Cited by 33
Self-citationWakahashi, K., Minagawa, K., Kawano, Y., Kawano, H., Suzuki, T., Ishii, S., Sada, A., Asada, N., Sato, M. M., Kato, S., et al. (2019) · Blood · doi:10.1182/blood-2018-09-876615 · Cited by 30
The lifelong natural history of clonal hematopoiesis and its links to myeloid neoplasia
Fabre, M. A., & Vassiliou, G. S. (2023) · Blood · doi:10.1182/blood.2023019964 · Cited by 32
The future of JAK inhibition in myelofibrosis and beyond
Mascarenhas, J. O., Cross, N. C. P., & Mesa, R. A. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.06.002 · Cited by 29
Self-citationVainchenker, W., Plo, I., Marty, C., Varghese, L. N., & Constantinescu, S. N. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1617129 · Cited by 29
Metadata
- Authors
- Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., Aziz, A., Godfrey, A. L., Hinton, J., Martincorena, I., Van Loo, P., Jones, A. V., Guglielmelli, P., Tarpey, P., Harding, H. P., Fitzpatrick, J. D., Goudie, C. T., Ortmann, C. A., Loughran, S. J., Raine, K., Jones, D. R., Butler, A. P., Teague, J. W., O'Meara, S., McLaren, S., Bianchi, M., Silber, Y., Dimitropoulou, D., Bloxham, D., Mudie, L., Maddison, M., Robinson, B., Keohane, C., Maclean, C., Hill, K., Orchard, K., Tauro, S., Du, M.-Q., Greaves, M., Bowen, D., Huntly, B. J. P., Harrison, C. N., Cross, N. C. P., Ron, D., Vannucchi, A. M., Papaemmanuil, E., Campbell, P. J., & Green, A. R.
- ORCID
- Nangalia, J.
- Massie, C.E.
- Baxter, E.J.
- Nice, F.L.
- Gundem, G.
- Wedge, D.C.
- Avezov, E.
- Kollmann, K.
- Kent, D.G.
- Godfrey, A.L.
- Hinton, J.
- Martincorena, I.
- Jones, A.V.
- Guglielmelli, P.
- Tarpey, P.
- Harding, H.P.
- Fitzpatrick, J.D.
- Loughran, S.J.
- Raine, K.
- Jones, D.R.
- Teague, J.W.
- McLaren, S.
- Hill, K.
- Orchard, K.
- Du, M.-Q.
- Greaves, M.
- Bowen, D.
- Huntly, B.J.P.
- Harrison, C.N.
- Cross, N.C.P.
- Ron, D.
- Vannucchi, A.M.
- Papaemmanuil, E.
- Campbell, P.J.
- Green, A.R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-12-19
- Volume
- 369
- Issue
- 25
- Pages
- 2391-2405
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3966280
- OpenAlex
- W2138709799
- Cited by
- 1,756
- References
- 40
- Citations by year
- 2026: 64 · 2025: 59 · 2024: 72 · 2023: 90 · 2022: 112 · 2021: 133 · 2020: 125 · 2019: 124 · 2018: 130 · 2017: 181 · 2016: 208 · 2015: 239 · 2014: 208 · 2013: 7
- FWCI
- 108.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- University of Salford Institutional Repository (University of Salford) (submittedVersion, cc-by)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Leukemia and Lymphoma Society
- Leukemia and Lymphoma Research
- University of Salford Manchester
- Wellcome Trust (079249, 100140, 093867, 084812)
- University Hospital Southampton NHS Foundation Trust
- Cancer Research UK (12526, 12765, 15488)
- National Institute for Health and Care Research (NF-SI-0512-10079)
- Kay Kendall Leukaemia Fund
- University of Southampton
- KU Leuven
- Università degli Studi di Firenze
- Associazione Italiana per la Ricerca sul Cancro
- Vlaamse regering
- Canadian Institutes of Health Research
- Medical Research Council
- Cambridge Institute for Medical Research, University of Cambridge
- NIHR Cambridge Biomedical Research Centre
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- calreticulin, CALR mutation, myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, myelofibrosis, myelodysplastic syndrome, endoplasmic reticulum chaperone, clonal evolution, hematopoietic stem and progenitor cells, somatic mutations
- MeSH terms
- Amino Acid Sequence, Bone Marrow Diseases, Exons, Humans, Leukemia, Myeloid, Molecular Sequence Data, Mutation, Myelodysplastic Syndromes, Neoplasms, Thrombocythemia, Essential, Polymerase Chain Reaction, Sequence Analysis, DNA, Calreticulin, Janus Kinase 2, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
